Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3255-3272

  Morrison, James H ^a   Guevara, Rebekah B ^a,b   Marcano, Adriana C ^a,c   Saenz, Dyana T ^a   Fadel, Hind J ^a   Rogstad, Daniel K ^a   Poeschla, Eric M ^a  

^a Mayo Clinic College of Medicine   (United States)

^b Dartmouth School of Medicine   (United States)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; BONE MARROW STROMAL ANTIGEN 2; MESSENGER RNA; TETHERIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CAT; CELL LINE; CELL SURFACE; CODON; CONTROLLED STUDY; DOG; FELINE IMMUNODEFICIENCY VIRUS; FERRET; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; SPECIES COMPARISON; TIGER; VIRION; VIRUS INFECTIVITY; VIRUS RELEASE; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; CAT DISEASES; CATS; DOGS; IMMUNODEFICIENCY VIRUS, FELINE; LENTIVIRUS INFECTIONS; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS; VIRION;

EID: 84894577734     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03814-13     Document Type: Article

References (96)

1. Groom HC, Yap MW, Galao RP, Neil SJ, Bishop KN. 2010. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc. Natl. Acad. Sci. U.S.A. 107:5166-5171. http://dx.doi.org/10.1073/pnas.0913650107.
2. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83:1837-1844. http://dx.doi.org/10.1128/JVI.02211-08.
3. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-11978. http://dx.doi.org/10.1128/JVI.01515-09.
4. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org/10.1038/nature06553.
5. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org/10.1016/j.chom.2008.03.001.
6. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 106:2886-2891. http://dx.doi.org/10.1073/pnas.0811014106.
7. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. 2009. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83:2382-2385. http://dx.doi.org/10.1128/JVI.01607-08.
8. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Fruh K. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83:9672-9681. http://dx.doi.org/10.1128/JVI.00597-09.
9. Douglas JL, Gustin JK, Viswanathan K, Mansouri M, Moses AV, Fruh K. 2010. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog. 6:e1000913. http://dx.doi.org/10.1371/journal.ppat.1000913.
10. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. 2010. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol. 18:388-396. http://dx.doi.org/10.1016/j.tim.2010.06.010.
11. Gupta RK, Towers GJ. 2009. A tail of tetherin: how pandemic HIV-1 conquered the world. Cell Host Microbe 6:393-395. http://dx.doi.org/10.1016/j.chom.2009.11.002.
12. Lim ES, Emerman M. 2009. Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2. J. Virol. 83:11673-11681. http://dx.doi.org/10.1128/JVI.00569-09.
13. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421. http://dx.doi.org/10.1016/j.chom.2009.10.004.
14. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. 2010. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13. http://dx.doi.org/10.1186/1742-4690-7-13.
15. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5:e1000429. http://dx.doi.org/10.1371/journal.ppat.1000429.
16. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67. http://dx.doi.org/10.1016/j.chom.2009.05.008.
17. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. 2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U.S.A. 106:20889-20894. http://dx.doi.org/10.1073/pnas.0907075106.
18. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51. http://dx.doi.org/10.1186/1742-4690-7-51.
19. Gottlinger HG, Dorfman T, Cohen EA, Haseltine WA. 1993. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. U.S.A. 90:7381-7385. http://dx.doi.org/10.1073/pnas.90.15.7381.
20. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. 1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64:621-629.
21. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. 2007. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 120:3850-3858. http://dx.doi.org/10.1242/jcs.003343.
22. Andrew AJ, Miyagi E, Kao S, Strebel K. 2009. The formation of cysteinelinked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 6:80. http://dx.doi.org/10.1186/1742-4690-6-80.
23. Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Hirano T, Tsuchiya M. 1999. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258:583-591. http://dx.doi.org/10.1006/bbrc.1999.0683.
24. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. 2003. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709. http://dx.doi.org/10.1034/j.1600-0854.2003.00129.x.
25. Fitzpatrick K, Skasko M, Deerinck TJ, Crum J, Ellisman MH, Guatelli J. 2010. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog. 6:e1000701. http://dx.doi.org/10.1371/journal.ppat.1000701.
26. Habermann A, Krijnse-Locker J, Oberwinkler H, Eckhardt M, Homann S, Andrew A, Strebel K, Krausslich HG. 2010. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84:4646-4658. http://dx.doi.org/10.1128/JVI.02421-09.
27. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511. http://dx.doi.org/10.1016/j.cell.2009.08.039.
28. Venkatesh S, Bieniasz PD. 2013. Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog. 9:e1003483. http://dx.doi.org/10.1371/journal.ppat.1003483.
29. Fadel H, Saenz D, Guevara R, Peretz M, Poeschla E. 2012. Productive replication and evolution of HIV-1 in ferret cells. J. Virol. 86:2312-2322.
30. McEwan WA, Schaller T, Ylinen LM, Hosie MJ, Towers GJ, Willett BJ. 2009. Truncation of TRIM5 in the Feliformia explains the absence of retroviral restriction in cells of the domestic cat. J. Virol. 16:8270-8275. http://dx.doi.org/10.1128/JVI.00670-09.
31. Sawyer SL, Emerman M, Malik HS. 2007. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog. 3:e197. http://dx.doi.org/10.1371/journal.ppat.0030197.
32. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573. http://dx.doi.org/10.1038/nature02777.
33. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853. http://dx.doi.org/10.1038/nature02343.
34. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T. 2008. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc. Natl. Acad. Sci. U.S.A. 105:3563-3568. http://dx.doi.org/10.1073/pnas.0709258105.
35. Wilson SJ, Webb BL, Ylinen LM, Verschoor E, Heeney JL, Towers GJ. 2008. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 105:3557-3562. http://dx.doi.org/10.1073/pnas.0709003105.
36. Best S, Le Tissier P, Towers G, Stoye JP. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382:826-829. http://dx.doi.org/10.1038/382826a0.
37. Lochelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rosler U, Battenberg M, Saib A, Flory E, Cichutek K, Munk C. 2005. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. U.S.A. 102:7982-7987. http://dx.doi.org/10.1073/pnas.0501445102.
38. Münk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O'Brien SJ, Lochelt M, Yuhki N. 2008. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 9:R48. http://dx.doi.org/10.1186/gb-2008-9-3-r48.
39. Münk C, Zielonka J, Constabel H, Kloke BP, Rengstl B, Battenberg M, Bonci F, Pistello M, Lochelt M, Cichutek K. 2007. Multiple restrictions of human immunodeficiency virus type 1 in feline cells. J. Virol. 81:7048-7060. http://dx.doi.org/10.1128/JVI.02714-06.
40. Stern MA, Hu C, Saenz DT, Fadel HJ, Sims O, Peretz M, Poeschla EM. 2010. Productive replication of Vif-chimeric HIV-1 in feline cells. J. Virol. 84:7378-7395. http://dx.doi.org/10.1128/JVI.00584-10.
41. Zielonka J, Marino D, Hofmann H, Yuhki N, Lochelt M, Munk C. 2010. Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids. J. Virol. 84:7312-7324. http://dx.doi.org/10.1128/JVI.00209-10.
42. Dietrich I, McMonagle EL, Petit SJ, Vijayakrishnan S, Logan N, Chan CN, Towers GJ, Hosie MJ, Willett BJ. 2011. Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J. Virol. 85:5840-5852. http://dx.doi.org/10.1128/JVI.00071-11.
43. Fukuma A, Abe M, Morikawa Y, Miyazawa T, Yasuda J. 2011. Cloning and characterization of the antiviral activity of feline tetherin/BST-2. PLoS One 6:e18247. http://dx.doi.org/10.1371/journal.pone.0018247.
44. Celestino M, Calistri A, Del Vecchio C, Salata C, Chiuppesi F, Pistello M, Borsetti A, Palu G, Parolin C. 2012. Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J. Virol. 86:6688-6700. http://dx.doi.org/10.1128/JVI.07037-11.
45. Kirchhoff F. 2009. Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution? Nat. Rev. Microbiol. 7:467-476. http://dx.doi.org/10.1038/nrmicro2111.
46. Cheney CM, Rojko JL, Kociba GJ, Wellman ML, Di Bartola SP, Rezanka LJ, Forman L, Mathes LE. 1990. A feline large granular lymphoma and its derived cell line. In Vitro Cell. Dev. Biol. 26:455-463. http://dx.doi.org/10.1007/BF02624087.
47. Crandell RA, Fabricant CG, Nelson-Rees WA. 1973. Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). In Vitro 9:176-185. http://dx.doi.org/10.1007/BF02618435.
48. Tokunaga K, Nishino Y, Oikawa H, Ishihara C, Mikami T, Ikuta K. 1992. Altered cell tropism and cytopathicity of feline immunodeficiency viruses in two different feline CD4-positive, CD8-negative cell lines. J. Virol. 66:3893-3898.
49. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, Poeschla E. 2005. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J. Cell Sci. 118:1733-1743. http://dx.doi.org/10.1242/jcs.02299.
50. Meehan AM, Saenz DT, Morrison JH, Garcia-Rivera JA, Peretz M, Llano M, Poeschla EM. 2009. LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors. PLoS Pathog. 5:e1000522. http://dx.doi.org/10.1371/journal.ppat.1000522.
51. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W, Poeschla EM. 2006. An essential role for LEDGF/p75 in HIV integration. Science 314:461-464. http://dx.doi.org/10.1126/science.1132319.
52. Poeschla E, Looney D. 1998. CXCR4 is required by a non-primate lentivirus: heterologous expression of feline immunodeficiency virus in human, rodent and feline cells. J. Virol. 72:6858-6866.
53. Poeschla E, Wong-Staal F, Looney D. 1998. Efficient transduction of nondividing cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4:354-357. http://dx.doi.org/10.1038/nm0398-354.
54. Talbott RL, Sparger EE, Lovelace KM, Fitch WM, Pedersen NC, Luciw PA, Elder JH. 1989. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 86:5743-5747. http://dx.doi.org/10.1073/pnas.86.15.5743.
55. Fadel HJ, Saenz D, Poeschla E. 2012. Construction and testing of orfA +/-FIV reporter viruses. Viruses 4:184-198. http://dx.doi.org/10.3390/v4010184.
56. Saenz DT, Barraza R, Loewen N, Teo W, Poeschla E. 2006. Production and use of feline immunodeficiency virus (FIV)-based lentiviral vectors, p 57-74. In Rossi J, Friedman T (ed), Gene transfer: a Cold Spring Harbor laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
57. Saenz DT, Teo W, Olsen JC, Poeschla E. 2005. Restriction of feline immunodeficiency virus by Ref1, LV1 and primate TRIM5a proteins. J. Virol. 79:15175-15188. http://dx.doi.org/10.1128/JVI.79.24.15175-15188.2005.
58. Sauter D, Hotter D, Engelhart S, Giehler F, Kieser A, Kubisch C, Kirchhoff F. 2013. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology 10:85. http://dx.doi.org/10.1186/1742-4690-10-85.
59. Loewen N, Barraza R, Whitwam T, Saenz DT, Kemler I, Poeschla E. 2003. FIV vectors. Methods Mol. Biol. 229:251-271. http://dx.doi.org/10.1385/1-59259-393-3:251.
60. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. 2010. Ebola virus glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84:7243-7255. http://dx.doi.org/10.1128/JVI.02636-09.
61. Saenz DT, Barraza R, Loewen N, Teo W, Poeschla EM. 2012. Production, harvest, and concentration of feline immunodeficiency virus-based lentiviral vector from cells grown in CF10 or CF2 devices. Cold Spring Harbor Protoc. 2012:118-123. http://dx.doi.org/10.1101/pdb.prot067546.
62. Nguyen KL, Llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. 2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319:163-175. http://dx.doi.org/10.1016/j.virol.2003.11.021.
63. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. 1986. Human alpha-and beta-interferon but not gamma-suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J. Interferon Res. 6:143-152. http://dx.doi.org/10.1089/jir.1986.6.143.
64. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83:9474-9485. http://dx.doi.org/10.1128/JVI.01089-09.
65. Benton MJ, Donoghue PC. 2007. Paleontological evidence to date the tree of life. Mol. Biol. Evol. 24:26-53. http://dx.doi.org/10.1093/molbev/msm017.
66. Johnson WE, Eizirik E, Pecon-Slattery J, Murphy WJ, Antunes A, Teeling E, O'Brien SJ. 2006. The late Miocene radiation of modern Felidae: a genetic assessment. Science 311:73-77. http://dx.doi.org/10.1126/science.1122277.
67. Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM. 1998. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem. 273:29210-29217. http://dx.doi.org/10.1074/jbc.273.44.29210.
68. Bego MG, Mercier J, Cohen EA. 2012. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J. Virol. 86:3513-3527. http://dx.doi.org/10.1128/JVI.06971-11.
69. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y, Doi T, Shimotohno K, Harada T, Nishida E, Hayashi H, Sugano S. 2003. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 22:3307-3318. http://dx.doi.org/10.1038/sj.onc.1206406.
70. Cocka LJ, Bates P. 2012. Identification of alternatively translated tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog. 8:e1002931. http://dx.doi.org/10.1371/journal.ppat.1002931.
71. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. 2012. Innate sensing of HIV-1 assembly by tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 12:633-644. http://dx.doi.org/10.1016/j.chom.2012.10.007.
72. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. 2013. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. J. Virol. 87:2046-2057. http://dx.doi.org/10.1128/JVI.02272-12.
73. Saenz DT, Barraza R, Loewen N, Teo W, Poeschla EM. 2012. Feline immunodeficiency virus-based lentiviral vectors. Cold Spring Harbor Protoc. 2012(1):71-76. http://dx.doi.org/10.1101/pdb.ip067579.
74. de Rozieres S, Mathiason CK, Rolston MR, Chatterji U, Hoover EA, Elder JH. 2004. Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade C. J. Virol. 78:8971-8982. http://dx.doi.org/10.1128/JVI.78.17.8971-8982.2004.
75. de Rozieres S, Thompson J, Sundstrom M, Gruber J, Stump DS, de Parseval AP, VandeWoude S, Elder JH. 2008. Replication properties of clade A/C chimeric feline immunodeficiency viruses and evaluation of infection kinetics in the domestic cat. J. Virol. 82:7953-7963. http://dx.doi.org/10.1128/JVI.00337-08.
76. Willett BJ, Picard L, Hosie MJ, Turner JD, Adema K, Clapham PR. 1997. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J. Virol. 71:6407-6415.
77. Chatterji U, de Parseval A, Elder JH. 2002. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J. Virol. 76: 9624-9634. http://dx.doi.org/10.1128/JVI.76.19.9624-9634.2002.
78. de Parseval A, Elder JH. 1999. Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity. J. Virol. 73:608-617.
79. Gemeniano MC, Sawai ET, Leutenegger CM, Sparger EE. 2003. Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity. J. Virol. 77:8819-8830. http://dx.doi.org/10.1128/JVI.77.16.8819-8830.2003.
80. Gemeniano MC, Sawai ET, Sparger EE. 2004. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 325:167-174. http://dx.doi.org/10.1016/j.virol.2004.05.007.
81. Hong Y, Fink E, Hu QY, Kiosses WB, Elder JH. 2010. OrfA downregulates feline immunodeficiency virus primary receptor CD134 on the host cell surface and is important in viral infection. J. Virol. 84:7225-7232. http://dx.doi.org/10.1128/JVI.00434-10.
82. Sparger EE, Shacklett BL, Renshaw-Gegg L, Barry PA, Pedersen NC, Elder JH, Luciw PA. 1992. Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology 187: 165-177. http://dx.doi.org/10.1016/0042-6822(92)90305-9.
83. Sundstrom M, Chatterji U, Schaffer L, de Rozieres S, Elder JH. 2008. Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology 371:394-404. http://dx.doi.org/10.1016/j.virol.2007.09.039.
84. Kemler I, Barraza R, Poeschla EM. 2002. Mapping of the encapsidation determinants of feline immunodeficiency virus. J. Virol. 76:11889-11903. http://dx.doi.org/10.1128/JVI.76.23.11889-11903.2002.
85. Tokarev A, Skasko M, Fitzpatrick K, Guatelli J. 2009. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res. Human Retroviruses 25:1197-1210. http://dx.doi.org/10.1089/aid.2009.0253.
86. Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. 2010. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6:e1000856. http://dx.doi.org/10.1371/journal.ppat.1000856.
87. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT. 2010. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 84:4089-4094. http://dx.doi.org/10.1128/JVI.01549-09.
88. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5:e1000450. http://dx.doi.org/10.1371/journal.ppat.1000450.
89. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410:582-608. http://dx.doi.org/10.1016/j.jmb.2011.04.042.
90. Hosie MJ, Klein D, Binley JM, Dunsford TH, Jarrett O, Neil JC, Knapp E, Giannecchini S, Matteucci D, Bendinelli M, Hoxie JA, Willett BJ. 2005. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. J. Virol. 79:1954-1957. http://dx.doi.org/10.1128/JVI.79.3.1954-1957.2005.
91. Kuhl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Sturzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pohlmann S. 2011. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204(Suppl 3):S850-S860. http://dx.doi.org/10.1093/infdis/jir378.
92. Fadel H, Poeschla E. 2011. Retroviral restriction and dependency factors in primates and carnivores. Vet. Immunol. Immunopathol. 143:179-189. http://dx.doi.org/10.1016/j.vetimm.2011.06.002.
93. Medina MF, Kobinger GP, Rux J, Gasmi M, Looney DJ, Bates P, Wilson JM. 2003. Lentiviral vectors pseudotyped with minimal filovirus enve-lopes increased gene transfer in murine lung. Mol. Ther. 8:777-789. http://dx.doi.org/10.1016/j.ymthe.2003.07.003.
94. Sinn PL, Hickey MA, Staber PD, Dylla DE, Jeffers SA, Davidson BL, Sanders DA, McCray PB, Jr. 2003. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J. Virol. 77:5902-5910. http://dx.doi.org/10.1128/JVI.77.10.5902-5910.2003.
95. Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J, Tanaka Y. 2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 284:15927-15941. http://dx.doi.org/10.1074/jbc.M109.005124.
96. Yang H, Wang J, Jia X, McNatt MW, Zang T, Pan B, Meng W, Wang HW, Bieniasz PD, Xiong Y. 2010. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. U.S.A. 107:18428-18432. http://dx.doi.org/10.1073/pnas.1011485107.